

#### **Pfizer Limited**

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

August 10, 2022

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai – 400 001 Scrip Code: 500680 The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051 Scrip Symbol: PFIZER

Dear Sirs,

# Sub: Intimation regarding resignation of Mr. S. Sridhar as the Managing Director of the Company

#### <u>Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015</u>

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby wishes to notify that Mr. S. Sridhar, Managing Director, has expressed his intention to take an early retirement and has tendered his resignation as the Managing Director of the Company. Mr. Sridhar will continue to serve in his current position of Managing Director for as long a period as required until the identification, selection and transition to the new leadership takes place in the Company. The effective date of his resignation shall be as agreed between Mr. Sridhar and the Board of Directors, and the same will be notified to you separately.

Over the past 14 years, Mr. Sridhar has led a number of key leadership positions in Pfizer Limited, including serving as the Company's Chief Financial Officer for a period of 8 years. Over the past 6 years, Mr. Sridhar has led Pfizer Limited as the Company's Managing Director and made significant contributions to the growth of the Company's portfolio, presence across India and reach to patients who have benefited from access to Pfizer therapies. Mr. Sridhar has also served as the Co-Chair of the FICCI Pharmaceuticals Committee and currently also serves as the President of the Organization of Pharmaceuticals Producers of India (OPPI).

The relevant details as per the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in the enclosed Annexure A.

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in Request you to please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

frigut

Prajeet Nair Company Secretary

Encl: A/a



# **Pfizer Limited**

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

#### ANNEXURE A

## Disclosures as per the Listing Regulations and SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015:

Sr. No.	Particulars	Details
1.	Name	Mr. S. Sridhar
2.	Reasons for change	Resignation of Mr. S. Sridhar (DIN: 05162648) as the Managing Director of the Company
3.	Date of Cessation	Mr. Sridhar will continue to serve in his current position of Managing Director for as long a period as required until the identification, selection and transition to the new leadership takes place in the Company. The effective date of his resignation shall be as agreed between Mr. Sridhar and the Board of Directors, and the same will be notified to you separately.
4.	Brief Profile (in case of appointment)	Not Applicable
5.	Relationship Inter-se Directors / Key Managerial Personnel (in case of appointment)	Not Applicable
6.	Number of shares held in the Company	Nil